FLAG-Ida Followed by Reduced-Intensity Total Body Irradiation and Donor Hematopoietic Cell Trans

The protocol mates an intensive chemotherapy backbone with a subsequent reduced-intensity conditioning regimen followed by donor hematopoietic cell transplantation (HCT) from an allogeneic donor.

This is followed a few days later by reduced-intensity total body irradiation (TBI) and donor HCT.

The study evaluates this upfront “FLAG-Ida then TBI plus donor HCT” approach rather than a conventional extended cytopenia-first strategy.

• Study aim and design: This is a phase II interventional trial evaluating the safety, tolerability, and preliminary efficacy of a sequential treatment approach in adults aged 60 and older with newly diagnosed adverse-risk AML or other high-grade myeloid neoplasms.
• Treatment sequence under investigation: Patients receive a defined chemotherapy regimen consisting of fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor, and idarubicin (collectively FLAG-Ida).

Donor HCT is recognized as a potentially curative component but is associated with prolonged cytopenias and associated infectious and bleeding risks, along with chronic toxicity and mortality.

The aim is to maintain anti-leukemic activity while curtailing the duration and severity of cytopenias, thereby potentially lowering infection and bleeding risks and enabling more patients to reach transplant.

• Clinical context: Despite advances and the availability of new agents since 2017, outcomes for older adults with adverse-risk AML and related high-grade myeloid cancers remain unfavorable.
• Rationale for the approach: The investigators propose to employ intense chemotherapy to address malignant burden, then introduce a reduced-intensity conditioning with TBI and proceed to donor HCT.

• Components of exposure: The chemotherapeutic regimen FLAG-Ida targets leukemic cells through distinct mechanisms aimed at halting proliferation and promoting cell death, with fludarabine and idarubicin contributing cytotoxic activity alongside high-dose cytarabine.
• Supportive strategy: G-CSF is incorporated to stimulate leukocyte recovery, intending to shorten periods of neutropenia and reduce infectious risk.
• Conditioning and transplant: Reduced-intensity TBI precedes donor HCT, with the goal of balancing anti-leukemic effect and transplant-related toxicity in the elderly cohort.

The study is currently recruiting, with an anticipated completion date in 2029.

• Population criteria: Adults aged 60 years and older with newly diagnosed adverse-risk AML or other high-grade myeloid neoplasms.
• Study type and purpose: An interventional, Phase II trial primarily designed as a treatment study.
• Enrollment and timeline: Estimated enrollment is 20 participants.

No numerical results are reported.

• Primary orientation: The trial aims to assess safety and tolerability, with secondary considerations around feasibility of delivering transplant after this integrated approach and potential signals of efficacy.
• Reported expectations: The investigators anticipate that intensified upfront chemotherapy followed by reduced-intensity TBI and donor HCT could be safe, tolerable, and potentially effective in this older, high-risk population.
• Limitations acknowledged in the source: The provided content does not specify quantitative outcomes, adverse event rates, or comparative effectiveness data.

• We lack trial results, including specific adverse events, overall response rates, relapse-free survival, and transplant-related mortality within the enrolled cohort.
• The generalizability of findings beyond the 60-and-older demographic with adverse-risk AML or similar myeloid neoplasms remains to be determined.